Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
May 08, 2026
XLV in a Short-Term Downtrend: Key Levels and Signals for Health Care ETF Traders

XLV in a Short-Term Downtrend: Key Levels and Signals for Health Care ETF Traders

Key Takeaways

  • XLV is in a short-term downtrend with a strong sell technical rating from moving averages and oscillators.
  • Price is consolidating near recent lows around 144-145, below key moving averages including the 20-day at 145.94 and 200-day at 147.23.
  • RSI(14) at approximately 46 indicates neutral momentum, neither overbought nor oversold.
  • MACD shows a sell signal, reflecting weakening momentum.
  • Key support zones at 144.04-144.43 and lower at 125-130; resistance at 145.06-145.69 and 137.5.
  • Volume has been average, with no significant spikes noted recently.

Understanding the Current Trend

The Health Care Select Sector SPDR Fund (XLV) has moved into a short-term downtrend after reaching a peak near 160 earlier this year. In my view, the price action over the last 30 days reflects a decline of about 0.60%, with a steeper 5.74% drop over the past quarter. Recently, the ETF tested lows around 142 before pulling back slightly to current levels near 144-145. This comes after a breakdown from higher levels, leaving price below multiple short-term moving averages. While the longer-term structure holds some constructive elements following a break of a descending trendline earlier, the recent weakness has me watching closely for signs of continuation or a potential reversal.

Critical Support and Resistance Zones

From what I see, traders are honing in on nearby pivot levels based on recent price action. Classical pivots indicate immediate support at S1 144.43, S2 144.04, and S3 143.80, with resistance at R1 145.06, R2 145.30, and R3 145.69. On a broader chart, stronger support lies in the 125-130 zone, where institutional absorption has occurred, and resistance clusters near 137.5-138, with an unfilled gap around 140 that could draw price higher on any upside move. Holding above 144 might help stabilize things, but a breach below could lead to deeper tests.

Moving Averages Pointing Lower

The moving averages largely signal sell, with 11 out of 12 showing bearish readings. The 5-day MA is at 144.56 (simple), the 20-day ranges from 145.13-145.94, the 50-day from 144.86-148.34, and the 200-day at 146.24-147.23. With price trading below these levels, the downtrend is confirmed, though the closeness to shorter MAs hints at possible consolidation. I think a crossover above the 20-day would mark the first bullish shift worth noting.

Momentum Indicators in Bearish Territory

RSI(14) is holding in neutral territory around 44-46 across sources, steering clear of oversold levels below 30. The MACD(12,26) at -0.06 with a sell signal highlights bearish divergence. Stochastic indicators also tilt toward sell, with STOCH(9,6) at 21.45 and Williams %R at -74 signaling downward pressure. Overall, the oscillators align with a strong sell rating, consistent with the technical summary.

Volume Trends and Market Activity

Recent daily volume has averaged 8-12 million shares, with the latest session at 7.4 million and no unusual spikes. Volume has tracked the price decline without picking up speed, which points to orderly selling rather than panic. The 20-day average volume sits around 8.4 million, reflecting steady activity in this defensive sector ETF. One thing that stands out is how this controlled volume supports the current consolidation.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

In my analysis, I’ve found Tickeron’s AI Daily Buy/Sell Signals particularly useful for digging deeper into XLV. These signals use artificial intelligence to analyze vast datasets, including technical indicators, price patterns, and historical trends. They help spot potential buy or sell opportunities by identifying recurring market behaviors, momentum shifts, and anomalies that might escape traditional methods. I rely on them to refine entry and exit points, confirm trend strength, and make better decisions in choppy markets. Updated daily, they add an objective edge to my chart work—worth checking out if you’re building AI-driven insights into your own strategy.

Technical Outlook and Levels to Monitor

This is important because market participants are focused on potential stabilization near 144 support, where a break above 145.30 resistance could bring short-term relief. Deeper support at 125-130 might draw buyers if tested, though failure there could expose the 127.35 52-week low. I’m watching RSI for any oversold bounces and MACD for histogram changes. Clearing the 137.5-140 gap on the upside would aim for prior highs, but trades sustained below 144 suggest further downside. Volatility is moderate, so volume confirmation around these levels will be key.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Related Ticker: XLV

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


XLV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for XLV turned positive on August 10, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on XLV as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 267 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XLV moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XLV broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Abbott Laboratories (NYSE:ABT), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY).

Industry description

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Market Cap

The average market capitalization across the State Street®HlthCrSelSectSPDR®ETF ETF is 105.86B. The market cap for tickers in the group ranges from 9.86B to 1.12T. LLY holds the highest valuation in this group at 1.12T. The lowest valued company is HSIC at 9.86B.

High and low price notable news

The average weekly price growth across all stocks in the State Street®HlthCrSelSectSPDR®ETF ETF was 129%. For the same ETF, the average monthly price growth was 150%, and the average quarterly price growth was 191%. MRNA experienced the highest price growth at 129%, while ALGN experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the State Street®HlthCrSelSectSPDR®ETF ETF was 71%. For the same stocks of the ETF, the average monthly volume growth was 40% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 43
Price Growth Rating: 30
SMR Rating: 58
Profit Risk Rating: 74
Seasonality Score: -28 (-100 ... +100)
View a ticker or compare two or three
XLV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
One Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.